{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:18:28Z","timestamp":1793884708379,"version":"4.7.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFD2401203"],"award-info":[{"award-number":["2022YFD2401203"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42176137"],"award-info":[{"award-number":["42176137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872906"],"award-info":[{"award-number":["81872906"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biopha.2024.116360","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T16:25:02Z","timestamp":1709137502000},"page":"116360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin"],"prefix":"10.1016","volume":"173","author":[{"given":"Zhenzhen","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo","family":"Qishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-6541","authenticated-orcid":false,"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib1","first-page":"7","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"Ca-a Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.biopha.2024.116360_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/14728222.2011.566216","article-title":"Overcoming drug resistance in pancreatic cancer","volume":"15","author":"Long","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.116360_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jso.25233","article-title":"FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: a cohort study","volume":"118","author":"Suker","year":"2018","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.21037\/jgo.2017.10.12","article-title":"The nab-paclitaxel\/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma","volume":"9","author":"Palacio","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib5","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2024.116360_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.34172\/apb.2020.066","article-title":"Tumor-associated macrophages: protumoral macrophages in inflammatory tumor microenvironment","volume":"10","author":"Malekghasemi","year":"2020","journal-title":"Adv. Pharm. Bull."},{"issue":"7","key":"10.1016\/j.biopha.2024.116360_bib7","doi-asserted-by":"crossref","first-page":"1596004","DOI":"10.1080\/2162402X.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.biopha.2024.116360_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.116360_bib9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/carcin\/bgaa128","article-title":"Distribution and prognostic impact of M1 macrophage on esophageal squamous cell carcinoma","volume":"42","author":"Jiang","year":"2021","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.biopha.2024.116360_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153550","article-title":"Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"Plos One"},{"key":"10.1016\/j.biopha.2024.116360_bib11","article-title":"CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures","author":"Lim","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.biopha.2024.116360_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1546-9","article-title":"M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide","volume":"15","author":"Genin","year":"2015","journal-title":"Bmc Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.116360_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020421","article-title":"Oligo-fucoidan prevents M2 macrophage differentiation and HCT116 tumor progression","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2024.116360_bib14","first-page":"99","article-title":"Sensitivity of clonogenic cells of human ovarian ascitic cancer to antitumor drugs","volume":"58","author":"Potapov","year":"1988","journal-title":"Arch. fur Geschwulstforsch."},{"key":"10.1016\/j.biopha.2024.116360_bib15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijbiomac.2018.09.059","article-title":"Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin","volume":"122","author":"Pawar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s40820-020-00531-0","article-title":"Nanoparticle-loaded polarized-macrophages for enhanced tumor targeting and cell-chemotherapy","volume":"13","author":"Hou","year":"2020","journal-title":"Nano-Micro Lett."},{"issue":"9","key":"10.1016\/j.biopha.2024.116360_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091493","article-title":"M1 macrophage-derived exosomes loaded with gemcitabine and deferasirox against chemoresistant pancreatic cancer","volume":"13","author":"Zhao","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/2001-1326-1-26","article-title":"Network insights on oxaliplatin anti-cancer mechanisms","volume":"1","author":"Alian","year":"2012","journal-title":"Clin. Transl. Med."},{"issue":"19","key":"10.1016\/j.biopha.2024.116360_bib19","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116360_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2019.10.020","article-title":"TLR 7\/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages","volume":"469","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116360_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12935-020-01233-8","article-title":"The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations","volume":"20","author":"Lin","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.biopha.2024.116360_bib22","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3390\/md13042327","article-title":"Fucoidan and cancer: a multifunctional molecule with anti-tumor potential","volume":"13","author":"Atashrazm","year":"2015","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/md17010032","article-title":"Fucoidan structure and activity in relation to anti-Cancer mechanisms","volume":"17","author":"van Weelden","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.biopha.2024.116360_bib24","article-title":"Fucoidan inhibits CCL22 production through NF-kappaB pathway in M2 macrophages: a potential therapeutic strategy for cancer","volume":"6","author":"Sun","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116360_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.114993","article-title":"A beta-1,3\/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator","volume":"222","author":"Su","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2024.116360_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-017-0106-7","article-title":"Tumor-associated macrophages, potential targets for cancer treatment","volume":"5","author":"Yang","year":"2017","journal-title":"Biomark. Res."},{"issue":"15","key":"10.1016\/j.biopha.2024.116360_bib27","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.7150\/thno.20251","article-title":"The anti-tumor effects of M1 macrophage-loaded poly (ethylene glycol) and gelatin-based hydrogels on hepatocellular carcinoma","volume":"7","author":"Guerra","year":"2017","journal-title":"Theranostics"},{"issue":"20","key":"10.1016\/j.biopha.2024.116360_bib28","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116360_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib30","first-page":"81","article-title":"Activation of NK cells in male cancer survivors by fucoidan extracted from Cladosiphon okamuranus","volume":"12","author":"Nagamine","year":"2020","journal-title":"Mol. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.biopha.2024.116360_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179125","article-title":"Enhancement of immune checkpoint inhibitor-mediated anti-cancer immunity by intranasal treatment of Ecklonia cava fucoidan against metastatic lung cancer","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2024.116360_bib32","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/01635581.2017.1362446","article-title":"The protective and immunomodulatory effects of fucoidan against 7,12-Dimethyl benz a anthracene-induced experimental mammary carcinogenesis through the PD1\/PDL1 signaling pathway in rats","volume":"69","author":"Xue","year":"2017","journal-title":"Nutr. Cancer- Int. J."},{"key":"10.1016\/j.biopha.2024.116360_bib33","article-title":"Fucoidan-supplemented diet potentiates immune checkpoint blockage by enhancing antitumor immunity","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib34","first-page":"251","article-title":"Anti-tumor activity of fucoidan is mediated by nitric oxide released from macrophages","volume":"40","author":"Takeda","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"23","key":"10.1016\/j.biopha.2024.116360_bib35","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/0008-5472.CAN-21-1572","article-title":"Hypoxia drives dihydropyrimidine dehydrogenase expression in macrophages and confers chemoresistance in colorectal cancer","volume":"81","author":"Malier","year":"2021","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116360_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CAD.0b013e3280104b11","article-title":"Cisplatin-treated murine peritoneal macrophages induce apoptosis in L929 cells: role of Fas-Fas ligand and tumor necrosis factor-tumor necrosis factor receptor 1","volume":"18","author":"Chauhan","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.biopha.2024.116360_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.canlet.2020.10.043","article-title":"TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1","volume":"498","author":"Shih","year":"2021","journal-title":"Cancer Lett."},{"issue":"Pt A","key":"10.1016\/j.biopha.2024.116360_bib38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijbiomac.2022.09.201","article-title":"Fucoidan, as an immunostimulator promotes M1 macrophage differentiation and enhances the chemotherapeutic sensitivity of capecitabine in colon cancer","volume":"222","author":"Deng","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2024.116360_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109636","article-title":"Sophoridine suppresses macrophage-mediated immunosuppression through TLR4\/IRF3 pathway and subsequently upregulates CD8(+) T cytotoxic function against gastric cancer","volume":"121","author":"Zhuang","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2024.116360_bib40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.immuni.2020.04.004","article-title":"Nucleic acid sensors as therapeutic targets for human disease","volume":"53","author":"McWhirter","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biopha.2024.116360_bib41","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116360_bib42","article-title":"Fucoidan induces Toll-like receptor 4-regulated reactive oxygen species and promotes endoplasmic reticulum stress-mediated apoptosis in lung cancer","volume":"7","author":"Hsu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116360_bib43","article-title":"Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance","volume":"3","author":"Seetharam","year":"2009","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"10.1016\/j.biopha.2024.116360_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071978","article-title":"Depletion of macrophages improves therapeutic response to gemcitabine in murine pancreas cancer","volume":"12","author":"Buchholz","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2024.116360_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.02.001","article-title":"Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer","volume":"29","author":"Halbrook","year":"2019","journal-title":"Cell Metab."},{"issue":"29","key":"10.1016\/j.biopha.2024.116360_bib46","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1038\/onc.2013.357","article-title":"Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase","volume":"33","author":"Weizman","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2024.116360_bib47","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2020.08.014","article-title":"Toll-like receptor 4 plays a key role in advanced glycation end products-induced M1 macrophage polarization","volume":"531","author":"Liu","year":"2020","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2024.116360_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01650","article-title":"TLR-3 stimulation skews M2 macrophages to M1 through IFN-alpha beta signaling and restricts tumor progression","volume":"9","author":"Vidyarthi","year":"2018","journal-title":"Front. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2026.119213","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000}},{"DOI":"10.1016\/j.biopha.2026.119213","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224002440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224002440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:26:12Z","timestamp":1793787972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224002440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":48,"alternative-id":["S0753332224002440"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116360","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116360"}}